Cargando…

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Loss of von Hippel–Lindau tumor suppressor gene is frequently observed in ccRCC and increases the expression of hypoxia‐inducible factors and their targets, including epidermal growth factor, vascular e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sekino, Yohei, Teishima, Jun, Liang, Gangning, Hinata, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087189/ https://www.ncbi.nlm.nih.gov/pubmed/36122306 http://dx.doi.org/10.1111/iju.15042

Ejemplares similares

Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma
por: Kobatake, Kohei, et al.
Publicado: (2022)

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
por: Zhang, Hailiang, et al.
Publicado: (2023)

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in  Clear - Cell Renal Cell Carcinoma (ccRCC)
por: Bielecka, Zofia F., et al.
Publicado: (2013)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress‐related tumorigenicity
por: Takemoto, Kenshiro, et al.
Publicado: (2022)

Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy
por: Sekino, Yohei, et al.
Publicado: (2022)

Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma
por: Li, Qinke, et al.
Publicado: (2020)

Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors
por: Lai, Yongchang, et al.
Publicado: (2023)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
por: Teishima, Jun, et al.
Publicado: (2021)

Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma
por: Gustafsson, Anna, et al.
Publicado: (2009)

Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas
por: Zhang, Qing, et al.
Publicado: (2019)

Editorial Comment to Testicular seminoma arising from infertile testes 6 years after microdissection testicular sperm extraction
por: Sekino, Yohei, et al.
Publicado: (2021)

Editorial Comment to Rare case of carcinoma in situ originated in right retrocaval ureter successfully managed with laparoscopic procedure
por: Sekino, Yohei, et al.
Publicado: (2020)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()
por: Jang, Jiryeon, et al.
Publicado: (2017)

High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma
por: WEI, CAN, et al.
Publicado: (2013)

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy
por: Dietz, Steffen, et al.
Publicado: (2017)

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients
por: Lukamowicz-Rajska, Magdalena, et al.
Publicado: (2016)

Evaluation of urinary catheters for effective manual bladder washout
por: Kobatake, Kohei, et al.
Publicado: (2022)

Association between copy-number alteration of +20q, −14q and −18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma
por: Wang, Liang, et al.
Publicado: (2020)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Editorial Comment to Knotted ureteral single‐J stent in a patient with ureterocutaneostomy
por: Sekino, Yohei, et al.
Publicado: (2021)

Editorial Comment to Rare case of immunoglobulin G4‐related disease arising in gonadal glands with long‐term remission without steroid treatment: Discussion and literature review
por: Sekino, Yohei, et al.
Publicado: (2021)

Claspin overexpression is associated with high‐grade histology and poor prognosis in renal cell carcinoma
por: Kobayashi, Go, et al.
Publicado: (2020)

KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer
por: Sekino, Yohei, et al.
Publicado: (2021)

Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
por: Tahiri, Andliena, et al.
Publicado: (2022)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
por: Watanabe, Kazuhiro, et al.
Publicado: (2021)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma
por: Kornakiewicz, Anna, et al.
Publicado: (2013)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r35uecgrtj0n7og8u4a5a8lkjo